The biopharmaceutical fermentation systems market size is estimated to be USD 13,301.9 million in 2022 and is expected to witness a CAGR of 7.29% during the forecast period 2022-2033. The increased utilization of human services, expanding elderly population, and rise in the prevalence of chronic diseases worldwide are factors contributing to the market growth. However, rising installation and maintenance costs for bioreactors is expected to hinder the growth.

Segmentation

By Application

Based on application, the market is segregated into recombinant proteins, antibiotics, probiotics, monoclonal antibodies and others. In 2022, the recombinant proteins segment held the highest market share owing to greater focus on developing innovative protein and immune response tranquillizer conjugates products.

By Product

On the basis of product, the market is bifurcated into downstream products and upstream products. In 2022, the downstream products segment held the highest market share due to advances in bio production technology, strict guidelines, continuous production, and single-use technologies are on the rise, and the maximum yield of microbial-based biopharmaceutical manufacturing is facilitated by the creation of genetically altered microbial strains.

By End User

Based on end user, the market is divided into contract research organizations, food industry, biopharmaceutical companies, academic research institutes, contract manufacturing organizations and others. In 2022, the biopharmaceutical companies segment held the highest market share owing to rising investments in biopharmaceutical products.

Regional Markets

In 2022, North America region accounted for the highest revenue in the biopharmaceutical fermentation systems market and is expected to maintain its dominance during the forecast period. This is attributed to the significant players’ existence, an increase in health care costs, a rise in the number of seniors, and a well-developed healthcare facility. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to a rise in the prevalence of chronic illnesses related to lifestyle, increasing urbanization, transformed financial profiles, and rise in health care investments and utilization.

Competitor Insights

Some of the key players operating in the biopharmaceutical fermentation systems market are Becton Dickinson (US), Danaher Corporation (US), Eppendorf AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), GE Healthcare(US), Lonza (Switzerland), Merck KGaA (Germany), Nova Biomedicals (US), Sartorius Stedim Biotech (Germany), and Thermo Fisher Scientific Inc. (US).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including application, product, and end user from 2022 to 2033.

Report Scope:

Segmentation: Biopharmaceutical Fermentation Systems Market Report 2022 – 2033

Application (Revenue, USD Million), 2022 – 2033

• Recombinant Proteins
• Antibiotics
• Probiotics
• Others

Product (Revenue, USD Million), 2022 – 2033

• Downstream Products
  • Chromatography
  • Consumables & Accessories
  • Filtration & Separation System
  • Other Downstream Products
• Upstream Products
  • Culture & Media Preparation
  • Fermenters
  • Process Monitoring Devices
  • Bioprocess Analyzers
  • Culture Media, Buffers & Inducers

End User (Revenue, USD Million), 2022 – 2033

• Contract Research Organizations
• Food Industry
• Biopharmaceutical Companies
• Academic Research Institutes
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA